Avacta Group

AVCT.LPhase 1

Wetherby, United KingdomFounded 2004avacta.com

Avacta Therapeutics is challenging conventional cancer drug delivery with its proprietary pre|CISION® platform, which aims to widen the therapeutic index of potent oncology drugs by ensuring release occurs specifically in the tumor microenvironment. The company's lead asset, faridoxorubicin (AVA6000), has demonstrated improved safety and tumor-specific drug concentration in Phase 1 trials, while its second program, AVA6103, incorporates a sustained-release mechanism. Avacta is advancing a pipeline of peptide and Affimer® drug conjugates, with a vision to expand the utility of existing cancer therapies across approximately 90% of solid tumors.

Market Cap

$30K

Founded

2004

Focus

AntibodiesBiologics

AVCT.L · Stock Price

USD 69.00+0.32 (+0.47%)

Historical price data

AI Company Overview

Technology Platform

The pre|CISION® platform is a tumor-activated drug delivery system using peptide-drug conjugates (PDCs) designed to be cleaved exclusively by the Fibroblast Activation Protein (FAP) enzyme in the tumor microenvironment, concentrating active drug at the tumor site while minimizing systemic exposure.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
AVA6000	Salivary Gland Tumor	Phase 1
AVA6103	Vulvar Adenocarcinoma	Phase 1

Funding History

Total raised: $78M

Placement$40MUndisclosedFeb 15, 2021

Placement$30MUndisclosedJul 15, 2020

IPO$8MUndisclosedJun 29, 2006

Opportunities

The primary growth opportunity lies in the broad applicability of the pre|CISION platform to ~90% of solid tumors.

Success with initial payloads (doxorubicin, exatecan) can pave the way for partnering to apply the technology to a wide array of other potent oncology drugs, creating a high-value platform licensing business.

Expansion into combination therapies and earlier lines of treatment represents further upside.

Risk Factors

Key risks include failure to demonstrate superior efficacy or a compelling safety profile in later-stage clinical trials, competition from established and next-generation ADCs, potential variability in FAP expression affecting drug response, and the ongoing need for significant capital to fund clinical development, leading to shareholder dilution.

Competitive Landscape

Avacta competes primarily with developers of Antibody-Drug Conjugates (ADCs) like Daiichi Sankyo and Gilead, and other tumor-targeting platforms. Its differentiation is based on the high specificity of FAP-activated release (vs. systemic activation for many ADCs), the potential for better tumor penetration with smaller PDCs, and a platform agnostic to payload, allowing rapid iteration and application to diverse chemotherapies.